Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -7.54
- Piotroski Score 3.00
- Grade N/A
- Symbol (BFRIW)
- Company Biofrontera Inc.
- Price $0.04
- Changes Percentage (0%)
- Change -$0
- Day Low $0.04
- Day High $0.04
- Year High $0.04
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/30/2023
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.30
- Trailing P/E Ratio -0.05
- Forward P/E Ratio -0.05
- P/E Growth -0.05
- Net Income $-20,131,000
Income Statement
Quarterly
Annual
Latest News of BFRIW
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
When Will Biofrontera Inc. (NASDAQ:BFRI) Become Profitable?
Biofrontera Inc., a biopharmaceutical company, may be close to achieving profitability. Analysts predict the company will break even in 2025 and generate profits in 2026....
By Yahoo! Finance | 2 months ago
